Clinical and epidemiological analysis of hepatitis C liver transplantation in Espírito Santo - Brazil

Authors

DOI:

https://doi.org/10.47456/rbps.v24i1.37780

Keywords:

Hepatitis C, Cirrhosis, Hepatocellular Carcinoma, Liver transplant

Abstract

Introduction: Chronic hepatitis C (HCV) is a high prevalence disease that can evolve to cirrhosis and to hepatocellular carcinoma (HCC), being considered an important cause of liver transplant. Objectives: trace the epidemiologic and clinical profile of transplanted patients with HCV cirrhosis. Methods: We retrospectively analyzed medical records of patients with HCV that performed liver transplants in a Hospital in Grande Vitória, in the state of Espírito Santo (Brazil) between the years of 2008 and 2020. The variables researched were number of transplants, gender, age, comorbidities, association with hepatitis B and HCC. Results: Of 359 transplants performed in that period, 61 (17%) were from patients with HCV. Of these, 62% also had another cause for cirrhosis, such as alcoholic hepatitis, non-alcoholic steatohepatitis, and hepatitis B virus (HBV). The average age was 55 years, with a clear predominance of males (77%). Twenty one patients (34,34%) evolved with HCC. The number of deaths was 21 (34,42%). The average number of HCV transplants over the years was 4.69 transplants/year. Thirty-five patients presented some comorbidity, the most common being diabetes mellitus, systemic arterial hypertension and smoking. There has been a slight reduction in the number of HCV transplants over the years. Conclusion: The HCV liver transplants were more prevalent in males, with average age of 55 years, and most patients had another associated disease. Furthermore, there was a reduction in the number of transplants, which could be explained by the use of the new antiviral therapy in the treatment of HCV.

Downloads

Download data is not yet available.

References

Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol; 2021.

Guss D, Sherigar J, Rosen P, Mohanty SR. Diagnosis and management of hepatitis C infection in primary care settings. Journal of Gener¬al Internal Medicine; 2018.

Pereira G, De Cunha A, Pinto F, Junior G, Ribeiro R, Coelho R. Boletim Epidemiológico Hepatites Virais. Brasília, DF: Jul 2019;50.

Jafri SM, Stuart CG. Epidemiology of hepatitis C. 2018; 10.1002/cld.783.

SecWretaria de Vigilância em Saúde (ES). Protocolo Clínico e Diretrizes Terapêuticas para Hepatite C e Coinfecções; 2018.

Pol S, Lagaye S. The remarkable history of the hepatitis C virus. Genes Immun; 2019.

Rockey DC, Cardwell SH, Goodman Z. Liver Biopsy; 2009.

Khatun M, Ray RB. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis; 2019.

Ahumada A, Rayón L, Usón C, Bañares R, Lopez SA. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fibrosis: who to screen and for how long? World J Gastroenterol; 2021.

Llovet MJ, Zucman-Rossi J, Pikarsky E, San¬gro B. Hepatocellular carcinoma. Nature Re¬views. New York, EUA: Apr, 2016.

Mücke MM, Mücke VT, Lange CM, Zeuzem S. Managing hepatitis C in patients with the complications of cirrhosis. Liver International; 2018.

Criado pela Universidade de Washington (EUA). Disponível on-line em: https://www. hepatitisc.uw.edu/page/clinical-calculators/ ctp.

Ministério da Saúde (BR). 2 ed. Doença hepática abordagem pericial isenção de imposto de renda. Disponível on-line em: http://sbhepatologia.org.br/associados/pdf/manual_hepatopatia_grave.pdf. Capturado em: 19 set. 2020.

Ruf A, Dirchwolf M, Freeman RB. From Child-Pugh to MELD score and beyond: taking a walk down memory lane. Annals of Hepatol¬ogy; 2022.

BRASIL, Portaria nº 2.600, 21 outubro de 2009. Aprova o Regulamento Técnico do Sistema Nacional de Transplantes. Diário Oficial [da] República Federativa do Brasil. Brasília: 22 out. 2009. Disponível em: http://bvsms.saude.gov.br/ bvs/saudelegis/gm/2009/prt2600_21_10_2009. html. Acesso em: 15 abr. 2019.

Dumitra S, Alabbad DI, Barkun SJ, Dumitra CT, Coutsinos D, et al. Hepatitis C infection and hepatocellular carcinoma in liver trans¬plantation: a 20-year experience. International Hepato-Pancreato-Biliary Association, Quebec, Canada: 2013.

Holzmanna I, Tovo CV, Minmé R, Leal MP, Kliemann MP, Ubirajara C, Aquin A, Araújo B, Almeida PRL. Effectiveness of chronic hep¬atitis C treatment with direct-acting antivirals in the Public Health System in Brazil. Braz J Infect Dis; 2018.

Chaves GC, Osório-De-Castro CGS, Oliveira MA. Compras públicas de medicamentos para hepatite C no Brasil no período de 2005 a 2015. Ciênc saúde coletiva. Rio de Janeiro: Aug. 2017; 22(8).

Goldberd D, Ditah IC, Saeian K, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the Waitlist for Liver Transplantation. AGA Institute; 2011.

Flemming J, Kim WR, Brosgart C, et al. Reduction in liver transplant wait-listing in the era of Direct-Acting Antiviral Therapy. Hepatology; 2016.

Nabatchikova EA, Abdurakhmanov DT, Ro¬zina TP, Nikulkina EN, Tanaschuk EL, Moiseev SV. Delisting and clinical outcomes of liver transplant candidates after hepatitis C virus eradication: a long-term single-center ex-perience. Clinics and Research in Hepatology and Gastroenterology; 2021.

Durand F, Francoz C. The future of liver transplantation for viral hepatitis. Liver International. France: 2017.

Melo APS, França EB, Malta DC, Garcia LP, Mooney M, Naghavi M. Mortalidade por cirrose, câncer hepático e transtornos devidos ao uso de álcool: Carga Global de Doenças no Brasil, 1990 e 2015. Revista Brasileira de Epidemiologia; 2017.

Caicedo LA, Delgado A, Garcia VH, Aristizabal AM, Gomez C, Jiménez DF, Sepulveda M, García JA, Rosso FAM, Alcazar KC, Villegas JI, Serrano O, Echeverria GJ. Liver transplantation in hepatitis co-Infected patients: experience from a south American transplant center. Transplantation Proceedings, v. 50, Colombia: 2018.

Alves V, Mello ES. Bogliolo Patologia, 9 ed. Rio de Janeiro, Guanabara: Kroogan; 2017; (cap 23).

Lam PH, Obirieze AC, Ortega G, Nwokeabia I. Characterization of hepatitis B and C among liver transplant recipients with hepatocellular carcinoma: an analysis of the Nationwide Inpatient Sample Database. Transplantation Proceedings, v. 48, Nova Iorque: 2016

Crespo G, Trota N, Londoño MC, Mauro E, Baliellas C, Castells L, et al. The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition. J Hepatol, v. 61; 2018.

Chhatwal J, Wang X, Ayer T, et al. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. Hepatology. Baltimore: 2016.

Published

2022-12-07

How to Cite

1.
Evangelista de Toledo V, Lopes Ferreira Silva Santos MC. Clinical and epidemiological analysis of hepatitis C liver transplantation in Espírito Santo - Brazil. RBPS [Internet]. 2022 Dec. 7 [cited 2024 Jul. 17];24(1):7-15. Available from: https://periodicos.ufes.br/rbps/article/view/37780

Issue

Section

Artigos Originais